RNTX revenueQ2 2026$0
RNTX revenue was $0 in fiscal Q2 2026 (ended Jun 30, 2026), compared with $0 a year earlier. For the full fiscal 2025 it was $0, compared with $0 in fiscal 2024.
Rein Therapeutics Inc. (RNTX) financials
For the twelve months ended Jun 30, 2026, Rein Therapeutics Inc. reported $0 of revenue and -$49.76M of net income.
- Revenue, TTM
- $0
- Net income, TTM
- -$49.76M
- EPS, diluted, TTM
- -$1.72
- Cash
- $8.54M
- Market cap
- $53.8M
FY2016FY2025
FY2016FY2025
FY2017FY2021
RNTX revenue and earnings growth
RNTX net incomeQ2 2026-$6.38M
RNTX net income was -$6.38M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$6.82M a year earlier. For the full fiscal 2025 it was -$49.87M, compared with -$62.88M in fiscal 2024.
RNTX EPSQ2 2026-$0.10
RNTX diluted EPS was -$0.10 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$1.96.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research and development | $11.03M | $14.25M | $3.99M | $17.97M | $17.01M | $11.17M | $17.66M | $18.45M | $14.24M | $10.28M |
| Selling, general and admin | $10.90M | $13.86M | $11.36M | $9.68M | $9.60M | $9.33M | $12.29M | $13.45M | $8.77M | $7.89M |
| Operating income | -$50.63M | -$65.11M | -$16.28M | -$27.65M | -$26.61M | -$20.50M | -$29.96M | -$31.90M | -$23.01M | -$18.17M |
| Income tax | -$712.0K | -$1.54M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$49.87M | -$62.88M | -$15.73M | -$27.33M | -$26.16M | -$27.33M | -$29.37M | -$31.55M | -$22.60M | -$18.12M |
| EPS, basic | -$1.96 | -$3.51 | -$3.42 | -$6.02 | -$117.80 | -$12.20 | -$24.00 | -$42.80 | -$60.80 | -$847.00 |
| EPS, diluted | -$1.96 | -$3.51 | -$3.42 | -$6.02 | -$117.80 | -$12.20 | -$24.00 | -$42.80 | -$60.80 | -$847.00 |
| Diluted shares | 25.4M | 17.9M | 4.6M | 4.5M | 222,016.9 | 1.7M | 1.2M | 736,909.65 | 372,153.9 | 21,484.3 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $3.21M | $12.87M | $17.34M | $5.19M | $3.60M | $7.05M | $5.31M | $10.63M | $11.86M | $20.80M |
| Short-term investments | $0 | - | - | - | - | - | - | - | - | - |
| Current assets | $4.33M | $13.66M | $18.27M | $21.87M | $48.18M | $16.33M | $19.55M | $21.77M | $51.84M | $21.07M |
| Goodwill | $6.33M | $6.33M | $6.33M | - | - | - | - | - | - | - |
| Total assets | $24.16M | $62.19M | $106.01M | $22.01M | $48.48M | $16.34M | $26.47M | $30.31M | $52.69M | $22.02M |
| Current liabilities | $6.18M | $5.75M | $4.38M | $3.38M | $4.51M | $3.96M | $5.84M | $5.37M | $4.89M | $4.07M |
| Total liabilities | $7.24M | $7.80M | $7.71M | $3.38M | $4.58M | $4.18M | $10.43M | $10.71M | $4.89M | $4.08M |
| Shareholders' equity | $16.92M | $54.39M | $98.30M | $18.62M | $43.90M | $12.16M | $16.05M | $19.60M | $47.80M | -$111.81M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$19.36M | -$22.29M | -$19.81M | -$24.86M | -$23.75M | -$20.48M | -$26.47M | -$27.93M | -$20.53M | -$15.01M |
| Capital expenditures | - | - | - | - | $157.0K | $5.0K | $151.0K | $4.42M | $142.0K | - |
| Free cash flow | - | - | - | - | -$23.91M | -$20.48M | -$26.63M | -$32.35M | -$20.67M | - |
| Investing cash flow | - | $0 | $16.20M | $26.46M | -$35.92M | $6.41M | -$2.81M | $24.69M | -$38.91M | -$25.0K |
| Financing cash flow | $9.76M | $17.82M | $15.79M | - | $55.66M | $15.80M | $23.96M | $2.52M | $50.59M | $31.99M |
| Stock-based compensation | $2.22M | $1.12M | $1.19M | $2.08M | $2.26M | $1.89M | $2.12M | $3.28M | $1.75M | $688.0K |
| Depreciation and amortization | $1.0K | $63.0K | $119.0K | $169.0K | $121.0K | $163.0K | $155.0K | $218.0K | $129.0K | $232.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on equity | -294.8% | -115.6% | -16.0% | -146.7% | -59.6% | -224.7% | -183.0% | -161.0% | -47.3% | - |
| Return on assets | -206.4% | -101.1% | -14.8% | -124.2% | -54.0% | -167.2% | -110.9% | -104.1% | -42.9% | -82.3% |
| Current ratio | 0.70 | 2.38 | 4.17 | 6.46 | 10.69 | 4.12 | 3.35 | 4.05 | 10.60 | 5.18 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research and development | $3.64M | $3.07M | $2.00M | $1.68M | $4.29M | $3.05M | $3.32M | $3.72M | $3.74M | $3.46M | $1.97M | $22.0K |
| Selling, general and admin | $2.44M | $2.16M | $1.96M | $3.81M | $2.58M | $2.56M | $2.48M | $2.35M | $5.30M | $3.74M | $5.33M | $1.96M |
| Operating income | -$6.08M | -$5.23M | -$32.66M | -$5.49M | -$6.87M | -$5.61M | -$42.80M | -$6.07M | -$9.04M | -$7.21M | -$7.29M | -$1.98M |
| Net income | -$6.38M | -$5.84M | -$31.97M | -$5.58M | -$6.82M | -$5.50M | -$40.98M | -$5.85M | -$8.94M | -$7.11M | -$7.34M | -$1.83M |
| EPS, basic | -$0.10 | -$0.19 | -$1.22 | -$0.21 | -$0.28 | -$0.25 | - | -$0.27 | -$0.45 | -$0.86 | -$1.58 | -$0.40 |
| EPS, diluted | -$0.10 | -$0.19 | -$1.22 | -$0.21 | -$0.28 | -$0.25 | - | -$0.27 | -$0.45 | -$0.86 | -$1.58 | -$0.40 |
| Diluted shares | 67.1M | 30.4M | - | 26.4M | 24.2M | 21.9M | - | 21.7M | 19.9M | 8.3M | - | 4.5M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $8.54M | $4.45M | $3.21M | $4.05M | $5.72M | $7.43M | $12.87M | $17.65M | $21.92M | $12.04M | $17.34M | $12.07M |
| Short-term investments | $32.10M | - | $0 | - | - | - | - | - | - | - | - | - |
| Current assets | $41.45M | $5.45M | $4.33M | $5.17M | $6.60M | $8.33M | $13.66M | $18.68M | $23.16M | $12.76M | $18.27M | $12.79M |
| Goodwill | $6.33M | $6.33M | $6.33M | $6.33M | $6.33M | $6.33M | $6.33M | $6.33M | $6.33M | $6.33M | $6.33M | - |
| Total assets | $65.97M | $26.29M | $24.16M | $53.71M | $57.48M | $57.63M | $62.19M | $104.22M | $109.40M | $99.19M | $106.01M | $12.82M |
| Current liabilities | $9.71M | $13.64M | $6.18M | $5.74M | $7.69M | $5.98M | $5.75M | $5.66M | $4.94M | $4.53M | $4.38M | $1.62M |
| Total liabilities | $10.77M | $14.70M | $7.24M | $7.52M | $9.47M | $7.75M | $7.80M | $8.98M | $8.38M | $7.86M | $7.71M | $1.62M |
| Shareholders' equity | $55.20M | $11.59M | $16.92M | $46.19M | $48.01M | $49.88M | $54.39M | $95.23M | $101.02M | $91.33M | $98.30M | $11.20M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.64M | -$3.42M | -$3.22M | -$3.55M | -$6.42M | -$6.17M | -$4.81M | -$3.82M | -$8.39M | -$5.27M | -$10.39M | -$1.64M |
| Investing cash flow | - | - | - | - | - | - | $0 | $0 | $0 | $0 | -$96.0K | $542.0K |
| Financing cash flow | $47.81M | $4.65M | $2.40M | $1.90M | $4.71M | $738.0K | $1.0K | -$446.0K | $18.26M | $0 | $15.79M | $0 |
| Stock-based compensation | $164.0K | $156.0K | $257.0K | $1.45M | $256.0K | $264.0K | $133.0K | $508.0K | $326.0K | $150.0K | $270.0K | $229.0K |
| Depreciation and amortization | - | - | $0 | $0 | $1.0K | $0 | $0 | $0 | $4.0K | $59.0K | $52.0K | $12.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 4.27 | 0.40 | 0.70 | 0.90 | 0.86 | 1.39 | 2.38 | 3.30 | 4.69 | 2.82 | 4.17 | 7.88 |
Source: XBRL data Rein Therapeutics Inc. files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-20, first reported Aug 11, 2023.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
RNTX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| RNTX | $0 | - | -$49.76M | - | $53.8M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
RNTX FAQ
6 questionsWhat is RNTX revenue?
Rein Therapeutics Inc. (RNTX) reported $0 of revenue for the twelve months ended Jun 30, 2026. Revenue for fiscal 2025 was $0.Is RNTX profitable?
No. Rein Therapeutics Inc. reported a net loss of $49.76M for the twelve months ended Jun 30, 2026.How much cash and debt does RNTX have?
Rein Therapeutics Inc. reported $8.54M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is RNTX earnings per share?
Diluted earnings per share were -$1.72 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did RNTX last report financial results?
The latest statements here come from Rein Therapeutics Inc.'s 10-Q filed on Aug 14, 2026, covering the period ended Jun 30, 2026.Where does this RNTX financial data come from?
Quantisnow builds these statements from the structured XBRL data Rein Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.